B. B. Fredholm, A. P. I. J.erman, K. A. Jacobson, K. N. Klotz et J. Linden, « International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors », Pharmacol. Rev., vol. 53, no 4, , p. 527–52 (PMID11734617, lire en ligne)
doi.org
dx.doi.org
B. B. Fredholm, M. P. Abbracchio, G. Burnstock, G. R. Dubyak, T. K. Harden, K. A. Jacobson, U. Schwabe et M. Williams, « Towards a revised nomenclature for P1 and P2 receptors », Trends Pharmacol. Sci., vol. 18, no 3, , p. 79–82 (PMID9133776, DOI10.1016/S0165-6147(96)01038-3)
Z. G. Gao et K. A. Jacobson, « Emerging adenosine receptor agonists », Expert Opinion on Emerging Drugs, vol. 12, no 3, , p. 479–92 (PMID17874974, DOI10.1517/14728214.12.3.479)
G. Haskó et P. Pacher, « A2A receptors in inflammation and injury: lessons learned from transgenic animals », Journal of Leukocyte Biology, vol. 83, no 3, , p. 447–55 (PMID18160539, PMCID2268631, DOI10.1189/jlb.0607359)
A. Kalda, L. Yu, E. Oztas et J. F. Chen, « Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease », Journal of the Neurological Sciences, vol. 248, nos 1–2, , p. 9–15 (PMID16806272, DOI10.1016/j.jns.2006.05.003)
K. Fuxe, S. Ferré, S. Genedani, R. Franco et L. F. Agnati, « Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function », Physiology & Behavior, vol. 92, nos 1–2, , p. 210–7 (PMID17572452, DOI10.1016/j.physbeh.2007.05.034)
S. N. Schiffmann, G. Fisone, R. Moresco, R. A. Cunha et S. Ferré, « Adenosine A2A receptors and basal ganglia physiology », Progress in Neurobiology, vol. 83, no 5, , p. 277–92 (PMID17646043, PMCID2148496, DOI10.1016/j.pneurobio.2007.05.001)
R. A. Cunha, S. Ferré, J. M. Vaugeois et J. F. Chen, « Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders », Current Pharmaceutical Design, vol. 14, no 15, , p. 1512–24 (PMID18537674, PMCID2423946, DOI10.2174/138161208784480090)
J. N. Peart et J. P. Headrick, « Adenosinergic cardioprotection: multiple receptors, multiple pathways », Pharmacology & Therapeutics, vol. 114, no 2, , p. 208–21 (PMID17408751, DOI10.1016/j.pharmthera.2007.02.004)
M. V. Cohen et J. M. Downey, « Adenosine: trigger and mediator of cardioprotection », Basic Research in Cardiology, vol. 103, no 3, , p. 203–15 (PMID17999026, DOI10.1007/s00395-007-0687-7)
Ferré S, « An update on the mechanisms of the psychostimulant effects of caffeine », Journal of Neurochemistry, vol. 105, no 4, , p. 1067–79 (PMID18088379, DOI10.1111/j.1471-4159.2007.05196.x)
Osadchii OE, « Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease », Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy, vol. 21, no 3, , p. 171–94 (PMID17373584, DOI10.1007/s10557-007-6014-6)
P. G. Baraldi, M. A. Tabrizi, S. Gessi et P. A. Borea, « Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility », Chemical Reviews, vol. 108, no 1, , p. 238–63 (PMID18181659, DOI10.1021/cr0682195)
G. Cristalli, C. Lambertucci, G. Marucci, R. Volpini, B. Dal et D. en, « A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists », Current Pharmaceutical Design, vol. 14, no 15, , p. 1525–52 (PMID18537675, DOI10.2174/138161208784480081)
K. A. Jacobson et Z. G. Gao, « Adenosine receptors as therapeutic targets », Nature Reviews. Drug Discovery, vol. 5, no 3, , p. 247–64 (PMID16518376, PMCID3463109, DOI10.1038/nrd1983)
Carroll SH, Ravid K (2013) Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors.Expert Reviews in Molecular Medicine 15. DOI10.1017/erm.2013.2
Carroll SH, Ravid K (2013) Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors. Expert Reviews in Molecular Medicine 15. DOI10.1017/erm.2013.2
nih.gov
ncbi.nlm.nih.gov
B. B. Fredholm, M. P. Abbracchio, G. Burnstock, G. R. Dubyak, T. K. Harden, K. A. Jacobson, U. Schwabe et M. Williams, « Towards a revised nomenclature for P1 and P2 receptors », Trends Pharmacol. Sci., vol. 18, no 3, , p. 79–82 (PMID9133776, DOI10.1016/S0165-6147(96)01038-3)
B. B. Fredholm, A. P. I. J.erman, K. A. Jacobson, K. N. Klotz et J. Linden, « International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors », Pharmacol. Rev., vol. 53, no 4, , p. 527–52 (PMID11734617, lire en ligne)
Z. G. Gao et K. A. Jacobson, « Emerging adenosine receptor agonists », Expert Opinion on Emerging Drugs, vol. 12, no 3, , p. 479–92 (PMID17874974, DOI10.1517/14728214.12.3.479)
G. Haskó et P. Pacher, « A2A receptors in inflammation and injury: lessons learned from transgenic animals », Journal of Leukocyte Biology, vol. 83, no 3, , p. 447–55 (PMID18160539, PMCID2268631, DOI10.1189/jlb.0607359)
A. Kalda, L. Yu, E. Oztas et J. F. Chen, « Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease », Journal of the Neurological Sciences, vol. 248, nos 1–2, , p. 9–15 (PMID16806272, DOI10.1016/j.jns.2006.05.003)
K. Fuxe, S. Ferré, S. Genedani, R. Franco et L. F. Agnati, « Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function », Physiology & Behavior, vol. 92, nos 1–2, , p. 210–7 (PMID17572452, DOI10.1016/j.physbeh.2007.05.034)
S. N. Schiffmann, G. Fisone, R. Moresco, R. A. Cunha et S. Ferré, « Adenosine A2A receptors and basal ganglia physiology », Progress in Neurobiology, vol. 83, no 5, , p. 277–92 (PMID17646043, PMCID2148496, DOI10.1016/j.pneurobio.2007.05.001)
R. A. Cunha, S. Ferré, J. M. Vaugeois et J. F. Chen, « Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders », Current Pharmaceutical Design, vol. 14, no 15, , p. 1512–24 (PMID18537674, PMCID2423946, DOI10.2174/138161208784480090)
J. N. Peart et J. P. Headrick, « Adenosinergic cardioprotection: multiple receptors, multiple pathways », Pharmacology & Therapeutics, vol. 114, no 2, , p. 208–21 (PMID17408751, DOI10.1016/j.pharmthera.2007.02.004)
M. V. Cohen et J. M. Downey, « Adenosine: trigger and mediator of cardioprotection », Basic Research in Cardiology, vol. 103, no 3, , p. 203–15 (PMID17999026, DOI10.1007/s00395-007-0687-7)
Ferré S, « An update on the mechanisms of the psychostimulant effects of caffeine », Journal of Neurochemistry, vol. 105, no 4, , p. 1067–79 (PMID18088379, DOI10.1111/j.1471-4159.2007.05196.x)
Osadchii OE, « Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease », Cardiovascular Drugs and Therapy / Sponsored by the International Society of Cardiovascular Pharmacotherapy, vol. 21, no 3, , p. 171–94 (PMID17373584, DOI10.1007/s10557-007-6014-6)
P. G. Baraldi, M. A. Tabrizi, S. Gessi et P. A. Borea, « Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility », Chemical Reviews, vol. 108, no 1, , p. 238–63 (PMID18181659, DOI10.1021/cr0682195)
G. Cristalli, C. Lambertucci, G. Marucci, R. Volpini, B. Dal et D. en, « A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists », Current Pharmaceutical Design, vol. 14, no 15, , p. 1525–52 (PMID18537675, DOI10.2174/138161208784480081)
K. A. Jacobson et Z. G. Gao, « Adenosine receptors as therapeutic targets », Nature Reviews. Drug Discovery, vol. 5, no 3, , p. 247–64 (PMID16518376, PMCID3463109, DOI10.1038/nrd1983)
yale.edu
senselab.med.yale.edu
Sauf si spécifié dans les cases, la référence correspondante est la suivante :senselab